Cardiotoxic effects of antitumor therapy for colorectal cancer
- Authors: Klimkin P.F.1, Shalenkova M.A.2, Ovchinnikova E.G.3
-
Affiliations:
- City Clinical Hospital Fifth
- City Clinical Hospital Thirty-Eighth
- Nizhny Novgorod Regional Clinical Oncology Dispensary
- Issue: Vol 34, No 11 (2023)
- Pages: 55-58
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/624402
- DOI: https://doi.org/10.29296/25877305-2023-11-14
- ID: 624402
Cite item
Abstract
Fluoropyrimidines (5-fluorouracil, capecitabine) are the main chemotherapeutic agents in the treatment of gastrointestinal oncologic pathology. However, therapy with these drugs may be associated with the development of cardiotoxic effects. The article discusses risk factors, the main proven mechanisms of cardiotoxic effects development; possible measures of primary and secondary prevention, peculiarities of fluoropyrimidines cardiotoxicity treatment are outlined.
Clinical cases are presented that demonstrate the complexity of the pathophysiological mechanisms of development of fluoropyrimidine (capecitabine) cardiotoxicity and the difficulties of its prediction. In this case, drugs with a vasodilating effect can be effectively used as part of secondary prevention.
Full Text
About the authors
P. F. Klimkin
City Clinical Hospital Fifth
Email: climckin2009@yandex.ru
ORCID iD: 0000-0002-0231-5909
Candidate of Medical Sciences
Russian Federation, Nizhny NovgorodM. A. Shalenkova
City Clinical Hospital Thirty-Eighth
Email: climckin2009@yandex.ru
ORCID iD: 0000-0003-0208-2401
Professor, MD
Russian Federation, Nizhny NovgorodE. G. Ovchinnikova
Nizhny Novgorod Regional Clinical Oncology Dispensary
Author for correspondence.
Email: climckin2009@yandex.ru
Candidate of Medical Sciences
Russian Federation, Nizhny NovgorodReferences
- Keramida K., Charalampopoulos G., Filippiadis D. et al. Cardiovascular complications of metastatic colorectal cancer treatment. J Gastrointest Oncol. 2019; 10 (4): 797–806. doi: 10.21037/jgo.2019.03.04
- Чиссов В.И. Онкология: Национальное руководство. Краткое издание. Под ред. В.И. Чиссова, М.И. Давыдова. М.: ГЭОТАР-Медиа, 2017; 576 с. [Chissov V.I. Onkologiya: Natsional'noe rukovodstvo. Kratkoe izdanie. Pod red. V.I. Chissova, M.I. Davydova. M.: GEOTAR-Media, 2017; 576 р. (in Russ.)].
- Давыдов М.И. Рациональная фармакотерапия в онкологии: руководство для практикующих врачей. Под ред. М.И. Давыдова, В.А. Горбуновой. М.: Литтерра, 2015; 844 с. [Davydov M.I. Ratsional'naya farmakoterapiya v onkologii: rukovodstvo dlya praktikuyushchikh vrachei. Pod red. M.I. Davydova, V.A. Gorbunovoi. M.: Litterra, 2015; 844 р. (in Russ.)].
- Васюк Ю.А., Гендлин Г.Е., Емелина Е.И. и др. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021; 26 (9): 4703 [Vasyuk YU. A., Gendlin G.E., Emelina E.I. et al. Consensus statement of russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021; 26 (9): 4703 (in Russ.)]. doi: 10.15829/1560-4071-2021-4703
- Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022; 43 (41): 4229–361. doi: 10.1093/eurheartj/ehac244
- Li C., Chen L., Chou C. et al. Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. Cardiovasc Toxicol. 2022; 22 (2): 130–40. doi: 10.1007/s12012-021-09708-4
- Peng J., Dong C., Wang C. et al. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer Commun (Lond). 2018; 38 (1): 22. doi: 10.1186/s40880-018-0292-1
- Abdel-Rahman O. 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2019; 18 (1): 58–63. doi: 10.1016/j.clcc.2018.10.006
- Dyhl-Polk A., Vaage-Nilsen M., Schou M. et al. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta Oncol. 2020; 59 (4): 475–83. doi: 10.1080/0284186X.2019.1711164
- Kwakman J.J., Simkens L.H., Mol L. et al. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer. 2017; 76: 93–9. doi: 10.1016/j.ejca.2017.02.009
- Saif M.W. Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity. Onco Targets Ther. 2020; 13: 10197–206. doi: 10.2147/OTT.S264156
- Anaka M., Abdel-Rahman O. Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment. Cancer Manag Res. 2022; 14: 273–85. doi: 10.2147/CMAR.S273544
- Zafar A., Drobni Z.D., Mosarla R. et al. The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. JACC CardioOncol. 2021; 3 (1): 101–9. doi: 10.1016/j.jaccao.2020.12.005
- Chakwop Ngassa H., Elmenawi K.A., Anil V. et al. Abnormal Dihydropyrimidine Dehydrogenase Activity as an Indicator of Potential 5-Fluorouracil Linked Cardiotoxicity in Colorectal Cancer Patients: Are Toxic Events Inevitable? Cureus. 2021; 13 (9): e17712. doi: 10.7759/cureus.17712
- Polk A., Vistisen K., Vaage-Nilsen M. et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014; 15: 47. doi: 10.1186/2050-6511-15-47
- Чазова И.Е., Тюляндин С.А., Виценя М.В. и др. Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Части II–V. Системные гипертензии. 2017; 14 (4): 6–19 [Chazova I.Y., Tyulyandin S.A., Vitsenia M.V. et al. Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Parts II–V. Systemic Hypertension. 2017; 14 (4): 6–19 (in Russ.)]. doi: 10.26442/2075-082X_14.4.6-19
- Upshaw J.N., O’Neill A., Carver J.R. et al. Fluoropyrimidine cardiotoxicity: time for a contemporaneous appraisal. Clin Colorectal Cancer. 2019; 18 (1): 44–51. doi: 10.1016/j.clcc.2018.08.001
- Virani S.A., Dent S., Brezden-Masley C. et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016; 32 (7): 831–41. doi: 10.1016/j.cjca.2016.02.078
- Koca D., Salman T., Unek I.T. et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy. 2011; 57 (5): 381–7. doi: 10.1159/000331645
- Jensen S.A., Hasbak P., Mortensen J. et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol. 2010; 28 (36): 5280–6. doi: 10.1200/JCO.2009.27.3953
- Виценя М.В., Агеев Ф.Т., Гиляров М.Ю. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли: Практические рекомендации RUSSCO #3s. 2022; 12: 78–100 [Vicenya M.V., Ageev F.T., Gilyarov M.Yu. et al. Clinical guidelines for the correction of cardiovascular toxicity of antitumor drug therapy. Malignant Tumoursis: Prakticheskie rekomendacii RUSSCO #3s. 2022; 12: 78–100 (in Russ.)]. doi: 10.18027/2224-5057-2022-12-3s2-78-100
- Ambrosy A.P., Kunz P.L., Fisher G.A. et al. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012; 110 (11): 1623–26. doi: 10.1016/j.amjcard.2012.07.026
- Clasen S.C., Ky B., O’Quinn R. et al. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017; 8 (6): 970–9. doi: 10.21037/jgo.2017.09.07
- Sara J.D., Kaur J., Khodadadi R. et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018; 10: 1758835918780140. doi: 10.1177/1758835918780140